BMS Collaborates with Systimmune and Entered into An Exclusive License Agreement For the Development of BL-B01D1
Shots:
- Under the agreement, SystImmune is eligible to receive $800M up front payment along with contingent payments of up to $500M. SystImmune may also receive further payments of up to $7.1B based on the achievement of certain milestones
- SystImmune will retain exclusive development & commercialization rights in Mainland China, where BMS will receive a royalty on net sales. SystImmune will be entitled to a tiered royalty on global net sales, excl. the US & Mainland China
- BL-B01D1, a bispecific topoisomerase inhibitor is undergoing P-I trial (BL-B01D1-LUNG101) globally. It aims to assess safety and efficacy in individuals with metastatic or unresectable NSCLC
Ref: BMS | Image: BMS
Related News:- BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
